The Role of New Technologies in Enabling Cell and Gene Therapies

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
A panel of experts will discuss product development and manufacturing challenges for cell and gene therapies, and technologies that are being developed to address these challenges. Panelists will include both end users that can discuss the needs for new technologies as well as technology providers.

The panel will discuss technologies for:
• Scalable and cost efficient production of viral vectors for gene therapy
• Non-viral approaches for gene therapy
• Scaling up to meet demand for autologous cell therapies

Chair: Doug Miller, Managing Director, BPTG
Daniella Kranjac, Co-Founder and Managing Director, Dynamk Capital LLC
Tim Kelly, President, Manufacturing, Asklepios BioPharmaceutical, Inc
Andy Ramelmeier, Executive Vice President, Technical Operations, Sangamo Therapeutics, Inc.
Ran Zheng, Chief Technical Officer, Orchard Therapeutics
Sponsored By